Silver Book Fact

AFib, an economic burden

Fact image

AFib is a major economic burden for the U.S. with at least $6.65 billion in healthcare costs attributable to the disease each year. This estimate may be low. One study estimates that Medicare alone pays $15.7 billion per year to treat newly diagnosed AFib patients.

Lee WC, Lamas GA, Balu S, et al. Direct Treatment Cost of Atrial Fibrillation in the Elderly American Population: A Medicare perspective. J Med Econ. 2008; 11(2). http://www.ncbi.nlm.nih.gov/pubmed/19450086

Coyne KS, Paramore C, Grandy S, et al. Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States. Value in Health. 2006; 9(5). http://www.ncbi.nlm.nih.gov/pubmed/16961553

Reference

Title
Direct Treatment Cost of Atrial Fibrillation in the Elderly American Population: A Medicare perspective
Publication
J Med Econ
Publication Date
2008
Authors
Lee WC, Lamas GA, Balu S, et al
Volume & Issue
Volume 11, Issue 2
Pages
281-98
URL
Read Full Resource
Title
Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States
Publication
Value in Health
Publication Date
2006
Authors
Coyne KS, Paramore C, Grandy S, et al
Volume & Issue
Volume 9, Issue 5
Pages
348-56
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Risk of stroke in people with AFib
    The risk of having a stroke increases 5-fold in individuals with AFib. Individuals with AFib also have more severe and recurrent strokes than those without the disease.  
  • AFib doubles dementia risk
    Individuals with AFib have a twice the risk of dementia.  
  • Atrial fibrillation prevalence projection, 2050
    Atrial fibrillation prevalence is projected to rise to between 5.6 and 12.1 million in 2050.  
  • Quality of life in AFib patients
    Individuals with AFib report substantially worse quality of life compared to those without the disease  
  • Hospitalization costs for patients with nonrecurrent ischemic stroke
    The cost of hospitalization for patients with nonrecurrent ischemic stroke is $4,991 more in patients with atrial fibrillation, than in patients without the disease.